Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1450, Issue 3, 1999, Pages 374-384

  Marbeuf Gueye, Carole ^a   Ettori, Dominique ^a   Priebe, Waldemar ^b   Kozlowski, Henryk ^c   Garnier Suillerot, Arlette ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF WROC AW   (Poland)

Author keywords

Doxorubicin; Kinetic; MRP; Multidrug resistance; P glycoprotein; Resistance factor

Indexed keywords

2 FLUOROIDARUBICIN; ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; GLYCOPROTEIN P; IDARUBICIN; PIRARUBICIN; UNCLASSIFIED DRUG; WP 401; WP 608; WP 656; WP 697; WP 715; WP 742;

ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; R FACTOR; TUMOR CELL;

ANTHRACYCLINES; CELL DIVISION; CELL MEMBRANE; DAUNORUBICIN; DNA-BINDING PROTEINS; DRUG RESISTANCE; HUMANS; KINETICS; MOLECULAR STRUCTURE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033057981     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(99)00060-9     Document Type: Article

References (30)

1. Bradley G., Juranka P.F., Ling V. Biochim. Biophys. Acta. 948:1988;87-128.
2. Gottesman M.M., Pastan I. Annu. Rev. Biochem. 62:1993;385-427.
3. Juliano R.L., Ling V. Biochim. Biophys. Acta. 455:1976;152-162.
4. Gottesman M.M., Pastan I., Ambudkar S.V. Curr. Biol. 6:1996;610-617.
5. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. Science. 258:1992;1650-1654.
6. Zaman G.J.R., Flens M.J., Van Leusden M.R., de Haas M., Mulder H.S., Lankelma J., Pinedo H.M., Scheper R.J., Baas F., Broxtermen H.J., Borst P. Proc. Natl. Acad. Sci. USA. 91:1994;8822-8826.
7. Higgins C.F. Annu. Rev. Cell Biol. 8:1992;67-113.
8. Cole S.P.C., Sparks K.E., Frazer K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Cancer Res. 54:1994;5902-5910.
9. Beck W.T., Cirtain M.C., Look A.T., Ashmun R.A. Cancer Res. 46:1986;778-784.
10. Inaba M., Maruyama E. Cancer Res. 48:1988;2064-2067.
11. Pereira E., Garnier-Suillerot A. Biochem. Pharmacol. 47:1994;1851-1857.
12. Ford F.M., Hait W.N. Pharmacol. Rev. 42:1991;155-159.
13. Garnier-Suillerot A. Curr. Pharm. Des. 1:1995;69-82.
14. Mankhetkorn S., Dubru F., Hesschenbrouck J., Fiallo M., Garnier-Suillerot A. Mol. Pharmacol. 49:1996;532-539.
15. Lozzio C.B., Lozzio B.B. Blood. 45:1975;321-334.
16. Zijlstra J.G., de Vries E.G.E., Mulder N.H. Cancer Res. 47:1987;1780-1784.
17. Priebe W. Curr. Pharm. Des. 1:1995;51-68.
18. Guidi A., Canfarini F., Giolitti A., Pasqui F., Pestellini V. F. Pure Appl. Chem. 66:1994;2319-2322.
19. Tarasiuk J., Frézard F., Garnier-Suillerot A., Gattegno L. Biochim. Biophys. Acta. 1013:1989;109-117.
20. Frézard F., Garnier-Suillerot A. Eur. J. Biochem. 196:1991;83-491.
21. Frézard F., Garnier-Suillerot A. Biochim. Biophys. Acta. 1091:1991;29-35.
22. Marbeuf-Gueye C., Broxterman H.J., Dubru F., Priebe W., Garnier-Suillerot A. Mol. Pharmacol. 53:1998;141-147.
23. Irving M., Miles G., Pettit L.D. Anal. Chim. Acta. 38:1967;475-482.
24. P. Gans, A. Vacca, A. Sabatini, J. Chem. Soc. Dalton Trans. (1985) 1195-1199.
25. Stein W. Physiol. Rev. 77:1997;545-590.
26. Beijnen J.H., Van der Nat J.M., Labadie R.P., Underberg W.J.M. Anti-cancer Res. 6:1986;39-44.
27. Beijnen J.H., Neef C., Meuwissen O.H.A.T., Rutten J.J.M.H., Rosing H., Underberg W.J.M. Am. J. Hosp. 43:1986;3022-3027.
28. Beijnen J.H., van der Houwen O.A.G.J., Underberg W.J.M. Int. J. Pharm. 32:1986;123-131.
29. Beijnen J.H., Potman R.P., van Ooijen R.D., Voskuilen R.J., Renema J., Underberg W.J.M. Int. J. Pharm. 34:1987;247-257.
30. Fiallo M., Laigle A., Borrel M.N., Garnier-Suillerot A. Biochem. Pharmacol. 45:1993;659-665.